Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:ALMS

Alumis Q1 2025 Earnings Report

Alumis logo
$7.10 -0.19 (-2.61%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$7.16 +0.06 (+0.79%)
As of 09/25/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Alumis EPS Results

Actual EPS
-$1.82
Consensus EPS
-$1.47
Beat/Miss
Missed by -$0.35
One Year Ago EPS
N/A

Alumis Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alumis Announcement Details

Quarter
Q1 2025
Date
5/14/2025
Time
After Market Closes
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Alumis' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Alumis' Q1 2025 Press ReleasePress Release
(8-K)
Alumis' Q1 2025 Quarterly reportQuarterly report
(10-Q)

Alumis Earnings Headlines

Pyxis Oncology (NASDAQ:PYXS) & Alumis (NASDAQ:ALMS) Head to Head Review
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031207
Alumis Inc. (ALMS) Latest Press Releases & Corporate News - Yahoo Finance
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/ALMS/press-releases/
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
September 27 at 1:00 AM  |  Profits Run (Ad)
Reviewing BridgeBio Pharma (NASDAQ:BBIO) & Alumis (NASDAQ:ALMS)
September 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029365
Alumis consensus price target decreased by 20.35% to $32.77
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/alumis-consensus-price-target-decreased-by-20-35-to-32-77/ar-AA2ci53G
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946049-alumis-inc-alms-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
See More Alumis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alumis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alumis and other key companies, straight to your email.

About Alumis

Alumis (NASDAQ:ALMS), Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s lead investigational product is ESK-001, a selective allosteric tyrosine kinase 2 (TYK2) inhibitor designed to regulate immune signaling while potentially avoiding some safety limitations associated with broader immunosuppressive treatments.

ESK-001 is being evaluated in clinical trials for moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing additional research programs intended to address other autoimmune and inflammatory conditions. The company does not currently have an approved commercial product, and its candidates remain subject to clinical testing and regulatory review.

Based in the United States, Alumis conducts its development activities through clinical research and collaborations with medical institutions and trial sites in multiple regions. The company became publicly traded on the Nasdaq under the symbol ALMS in 2024.

View Alumis Profile
Earnings Tools